Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple mye...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Oriol, Albert, Larocca, Alessandra, Bladé, Joan, Cavo, Michele, Rodriguez-Otero, Paula, Leleu, Xavier, Nadeem, Omar, Hiemenz, John W., Hassoun, Hani, Touzeau, Cyrille, Alegre, Adrián, Paner, Agne, Maisel, Christopher, Mazumder, Amitabha, Raptis, Anastasios, Moreb, Jan S., Anderson, Kenneth C., Laubach, Jacob P., Thuresson, Sara, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A., Mateos, María-Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078327/
https://www.ncbi.nlm.nih.gov/pubmed/33296242
http://dx.doi.org/10.1200/JCO.20.02259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078327/
https://www.ncbi.nlm.nih.gov/pubmed/33296242
http://dx.doi.org/10.1200/JCO.20.02259

Ejemplares similares